Project Grant R21CA300890
Award Date 6/5/26
Completion Date 5/31/28
Dollars Obligated $389K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14611, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $697,131 to Icahn School of Medicine at Mount Sinai under the Cancer Biology Research program (CFDA 93.396) to conduct a five-year research initiative examining immunosuppressive mechanisms in colorectal cancer (CRC). The project, which commenced May 1, 2026 and extends through April 30, 2031, will deliver fundamental research findings on how myeloid cells and cancer-associated fibroblasts interact to promote immune...
- Federal Grant Award Summary The University of Rochester received a $639,098 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and concluding July 31, 2030. This award supports research targeting intrinsic and extrinsic barriers to metastatic pancreatic ductal adenocarcinoma (PDAC) treatment. The project develops and evaluates an innovative combination therapy approach designed to overcome treatment resistance...
- Federal Grant Award Summary Cold Spring Harbor Laboratory received a $704,182 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 16, 2026, with an ultimate completion date of May 31, 2031. The award funds fundamental research aimed at elucidating the non-mutational mechanisms underlying the benign-to-malignant transition in colorectal cancer (CRC). The research deliverables include the development and utilization...
- Federal Grant Award Summary The University of Rochester received a $624,494 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, through June 30, 2031. The award supports research focused on developing and evaluating an innovative combined treatment strategy for pancreatic ductal adenocarcinoma (PDAC). The research deliverables involve investigating a novel therapeutic approach that combines stereotactic body...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $681,818 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Treatment Research program (CFDA 93.395) for the period June 2, 2026 through May 31, 2031. The research focuses on restoring anti-tumor immunity in chromosomally unstable tumors through investigation of the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) signaling pathway. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The University of Connecticut Health Center received a $484,918 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. The grant funds fundamental research investigating the IL-17-YBX1 signaling pathway's role in controlling tumor-infiltrating regulatory T cell (Treg) function and colorectal cancer (CRC) development. The research will elucidate how IL-17 cytokines...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $733,864 to the Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) to identify and characterize stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR) in tumor immunosurveillance. The five-year project, initiated June 1, 2026, and extending through May 31, 2031, will employ high-throughput CRISPR-based screening approaches to...